File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1111/j.1400-1746.2005.03889.x
- Scopus: eid_2-s2.0-21244433881
- PMID: 15946144
- WOS: WOS:000229282400020
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Low-dose rabeprazole, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese patients
Title | Low-dose rabeprazole, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese patients |
---|---|
Authors | |
Keywords | Amoxicillin Eradication Helicobacter pylori Metronidazole Rabeprazole |
Issue Date | 2005 |
Publisher | Wiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JGH |
Citation | Journal Of Gastroenterology And Hepatology, 2005, v. 20 n. 6, p. 935-940 How to Cite? |
Abstract | Background: Rabeprazole in combination with amoxicillin and metronidazole (RAM) has been shown to be an effective second-line treatment of Helicobacter pylori infection. The effects were compared of 7-day low-dose and high dose rabeprazole in RAM for the primary treatment of H. pylori infection in Chinese patients. Methods: Helicobacter pylori-positive dyspeptic patients were randomized to receive either (i) rabeprazole 10 mg, amoxicillin 1000 mg and metronidazole 400 mg (RAM-10) or (ii) high-dose rabeprazole 20 mg, amoxicillin 1000 mg and metronidazole 400 mg (RAM-20), each given twice daily for 7 days. Helicobacter pylori eradication was confirmed by 13C-urea breath test 5 weeks after stopping medications. Side-effects of treatments were documented. Results: A total of 120 patients were eligible for analysis. By intention-to-treat and per-protocol analysis, the eradication rates were 83% and 86% in the RAM-10 group and 75% and 76% in the RAM-20 group, respectively (P = 0.26 and P = 0.17). Both regimens were well-tolerated and compliance was >98% in both groups. Conclusions: Low-dose rabeprazole in combination with amoxicillin and metronidazole is an effective, economical and well-tolerated therapy for the treatment of H. pylori infection in Chinese population. © 2005 Blackwell Publishing Asia Pty Ltd. |
Persistent Identifier | http://hdl.handle.net/10722/78069 |
ISSN | 2023 Impact Factor: 3.7 2023 SCImago Journal Rankings: 1.179 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wong, WM | en_HK |
dc.contributor.author | Huang, J | en_HK |
dc.contributor.author | Xia, HHX | en_HK |
dc.contributor.author | Fung, FMY | en_HK |
dc.contributor.author | Tong, TSM | en_HK |
dc.contributor.author | Cheung, KL | en_HK |
dc.contributor.author | Ho, VYK | en_HK |
dc.contributor.author | Lai, KC | en_HK |
dc.contributor.author | Chan, CK | en_HK |
dc.contributor.author | Chan, AOO | en_HK |
dc.contributor.author | Hui, CK | en_HK |
dc.contributor.author | Lam, SK | en_HK |
dc.contributor.author | Wong, BCY | en_HK |
dc.date.accessioned | 2010-09-06T07:38:49Z | - |
dc.date.available | 2010-09-06T07:38:49Z | - |
dc.date.issued | 2005 | en_HK |
dc.identifier.citation | Journal Of Gastroenterology And Hepatology, 2005, v. 20 n. 6, p. 935-940 | en_HK |
dc.identifier.issn | 0815-9319 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/78069 | - |
dc.description.abstract | Background: Rabeprazole in combination with amoxicillin and metronidazole (RAM) has been shown to be an effective second-line treatment of Helicobacter pylori infection. The effects were compared of 7-day low-dose and high dose rabeprazole in RAM for the primary treatment of H. pylori infection in Chinese patients. Methods: Helicobacter pylori-positive dyspeptic patients were randomized to receive either (i) rabeprazole 10 mg, amoxicillin 1000 mg and metronidazole 400 mg (RAM-10) or (ii) high-dose rabeprazole 20 mg, amoxicillin 1000 mg and metronidazole 400 mg (RAM-20), each given twice daily for 7 days. Helicobacter pylori eradication was confirmed by 13C-urea breath test 5 weeks after stopping medications. Side-effects of treatments were documented. Results: A total of 120 patients were eligible for analysis. By intention-to-treat and per-protocol analysis, the eradication rates were 83% and 86% in the RAM-10 group and 75% and 76% in the RAM-20 group, respectively (P = 0.26 and P = 0.17). Both regimens were well-tolerated and compliance was >98% in both groups. Conclusions: Low-dose rabeprazole in combination with amoxicillin and metronidazole is an effective, economical and well-tolerated therapy for the treatment of H. pylori infection in Chinese population. © 2005 Blackwell Publishing Asia Pty Ltd. | en_HK |
dc.language | eng | en_HK |
dc.publisher | Wiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JGH | en_HK |
dc.relation.ispartof | Journal of Gastroenterology and Hepatology | en_HK |
dc.subject | Amoxicillin | - |
dc.subject | Eradication | - |
dc.subject | Helicobacter pylori | - |
dc.subject | Metronidazole | - |
dc.subject | Rabeprazole | - |
dc.subject.mesh | 2-Pyridinylmethylsulfinylbenzimidazoles | en_HK |
dc.subject.mesh | Adolescent | en_HK |
dc.subject.mesh | Adult | en_HK |
dc.subject.mesh | Aged | en_HK |
dc.subject.mesh | Aged, 80 and over | en_HK |
dc.subject.mesh | Amoxicillin - administration & dosage - therapeutic use | en_HK |
dc.subject.mesh | Anti-Bacterial Agents - administration & dosage - therapeutic use | en_HK |
dc.subject.mesh | Benzimidazoles - administration & dosage - therapeutic use | en_HK |
dc.subject.mesh | Biopsy | en_HK |
dc.subject.mesh | Dose-Response Relationship, Drug | en_HK |
dc.subject.mesh | Drug Therapy, Combination | en_HK |
dc.subject.mesh | Dyspepsia - drug therapy - epidemiology - etiology | en_HK |
dc.subject.mesh | Endoscopy, Gastrointestinal | en_HK |
dc.subject.mesh | Enzyme Inhibitors - administration & dosage - therapeutic use | en_HK |
dc.subject.mesh | Female | en_HK |
dc.subject.mesh | Helicobacter Infections - complications - drug therapy - epidemiology | en_HK |
dc.subject.mesh | Helicobacter pylori - isolation & purification | en_HK |
dc.subject.mesh | Humans | en_HK |
dc.subject.mesh | Male | en_HK |
dc.subject.mesh | Metronidazole - administration & dosage - therapeutic use | en_HK |
dc.subject.mesh | Middle Aged | en_HK |
dc.subject.mesh | Omeprazole - administration & dosage - analogs & derivatives - therapeutic use | en_HK |
dc.subject.mesh | Prevalence | en_HK |
dc.subject.mesh | Proton-Translocating ATPases - antagonists & inhibitors | en_HK |
dc.subject.mesh | Pyloric Antrum - microbiology - pathology | en_HK |
dc.subject.mesh | Retrospective Studies | en_HK |
dc.subject.mesh | Treatment Outcome | en_HK |
dc.title | Low-dose rabeprazole, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese patients | en_HK |
dc.type | Article | en_HK |
dc.identifier.openurl | http://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0815-9319&volume=20&issue=6&spage=935&epage=940&date=2005&atitle=Low-dose+rabeprazole,+amoxicillin+and+metronidazole+triple+therapy+for+the+treatment+of+Helicobacter+pylori+infection+in+Chinese+patients | en_HK |
dc.identifier.email | Wong, BCY:bcywong@hku.hk | en_HK |
dc.identifier.authority | Wong, BCY=rp00429 | en_HK |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1111/j.1400-1746.2005.03889.x | en_HK |
dc.identifier.pmid | 15946144 | - |
dc.identifier.scopus | eid_2-s2.0-21244433881 | en_HK |
dc.identifier.hkuros | 99103 | en_HK |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-21244433881&selection=ref&src=s&origin=recordpage | en_HK |
dc.identifier.volume | 20 | en_HK |
dc.identifier.issue | 6 | en_HK |
dc.identifier.spage | 935 | en_HK |
dc.identifier.epage | 940 | en_HK |
dc.identifier.isi | WOS:000229282400020 | - |
dc.publisher.place | Australia | en_HK |
dc.identifier.scopusauthorid | Wong, WM=7403972413 | en_HK |
dc.identifier.scopusauthorid | Huang, J=7403635051 | en_HK |
dc.identifier.scopusauthorid | Xia, HHX=8757161400 | en_HK |
dc.identifier.scopusauthorid | Fung, FMY=7003833944 | en_HK |
dc.identifier.scopusauthorid | Tong, TSM=7102587364 | en_HK |
dc.identifier.scopusauthorid | Cheung, KL=8612107300 | en_HK |
dc.identifier.scopusauthorid | Ho, VYK=8612107400 | en_HK |
dc.identifier.scopusauthorid | Lai, KC=7402135595 | en_HK |
dc.identifier.scopusauthorid | Chan, CK=7404813960 | en_HK |
dc.identifier.scopusauthorid | Chan, AOO=7403167965 | en_HK |
dc.identifier.scopusauthorid | Hui, CK=7202876933 | en_HK |
dc.identifier.scopusauthorid | Lam, SK=7402279473 | en_HK |
dc.identifier.scopusauthorid | Wong, BCY=7402023340 | en_HK |
dc.identifier.issnl | 0815-9319 | - |